195 related articles for article (PubMed ID: 20847676)
41. Effects of subconjunctival tocilizumab versus bevacizumab in treatment of corneal neovascularization in rabbits.
Yoo AR; Chung SK
Cornea; 2014 Oct; 33(10):1088-94. PubMed ID: 25119962
[TBL] [Abstract][Full Text] [Related]
42. Corneal graft surgery combined with subconjunctival bevacizumab (avastin).
Symes RJ; Poole TR
Cornea; 2010 Jun; 29(6):691-3. PubMed ID: 20458243
[TBL] [Abstract][Full Text] [Related]
43. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation.
Shin JP; Lee JW; Sohn BJ; Kim HK; Kim SY
J Glaucoma; 2009; 18(8):589-94. PubMed ID: 19826387
[TBL] [Abstract][Full Text] [Related]
44. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
[TBL] [Abstract][Full Text] [Related]
45. The effect of topical bevacizumab as an adjunctive therapy for corneal neovascularization.
Asena L; Akova YA; Cetinkaya A; Kucukerdonmez C
Acta Ophthalmol; 2013 May; 91(3):e246-8. PubMed ID: 22998029
[No Abstract] [Full Text] [Related]
46. Avastin use in high risk corneal transplantation.
Vassileva PI; Hergeldzhieva TG
Graefes Arch Clin Exp Ophthalmol; 2009 Dec; 247(12):1701-6. PubMed ID: 19680676
[TBL] [Abstract][Full Text] [Related]
47. Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab.
Dekaris I; Gabrić N; Drača N; Pauk-Gulić M; Miličić N
Graefes Arch Clin Exp Ophthalmol; 2015 Feb; 253(2):287-94. PubMed ID: 25398659
[TBL] [Abstract][Full Text] [Related]
48. Bilateral response after unilateral subconjunctival bevacizumab injection in a child with Stevens-Johnson syndrome.
Kesarwani S; Sahu SK; Basu S
J AAPOS; 2012 Jun; 16(3):309-11. PubMed ID: 22459106
[TBL] [Abstract][Full Text] [Related]
49. Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Adan A; Berrocal MH; Espinoza JV; Maia M; Wu L; Roca JA; Quiroz-Mercado H; Ruiz-Moreno JM; Serrano MA;
Retina; 2011 Feb; 31(2):353-63. PubMed ID: 20890239
[TBL] [Abstract][Full Text] [Related]
50. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
[TBL] [Abstract][Full Text] [Related]
51. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.
Habot-Wilner Z; Barequet IS; Ivanir Y; Moisseiev J; Rosner M
Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103
[TBL] [Abstract][Full Text] [Related]
52. Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis.
Papathanassiou M; Theodoropoulou S; Analitis A; Tzonou A; Theodossiadis PG
Cornea; 2013 Apr; 32(4):435-44. PubMed ID: 22668582
[TBL] [Abstract][Full Text] [Related]
53. Multiple subconjunctival bevacizumab for advanced primary pterygium.
Saxena S; Vishwkarma K; Khattri M; Kishore P
Ann Ophthalmol (Skokie); 2010; 42 Spec No():28-30. PubMed ID: 21138148
[TBL] [Abstract][Full Text] [Related]
54. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
55. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
Wakabayashi T; Ikuno Y; Gomi F
Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
[TBL] [Abstract][Full Text] [Related]
56. Subconjunctival bevacizumab for corneal neovascularization secondary to topical anesthetic abuse.
Georgakopoulos CD; Vasilakis P; Makri OE; Beredima E; Pharmakakis N
Cutan Ocul Toxicol; 2011 Dec; 30(4):320-2. PubMed ID: 21517719
[TBL] [Abstract][Full Text] [Related]
57. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
58. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
59. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
[TBL] [Abstract][Full Text] [Related]
60. The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization.
Acar BT; Halili E; Acar S
Int Ophthalmol; 2013 Oct; 33(5):507-13. PubMed ID: 23404727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
